Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease
Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of Canadian Patent #3,024,728 for its Linebacker™ technology platform.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Impact BioMedical Inc. (NYSE: IBO) has announced the issuance of Canadian Patent #3,024,728 for its Linebacker™ technology platform. The patent, titled "Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders," covers novel enhanced phenolic compounds and pharmaceutical compositions for treating inflammatory diseases.
The Linebacker™ technology targets key inflammatory pathways, potentially reducing inflammation and providing symptomatic relief with fewer side effects compared to traditional anti-inflammatory medications. The patent includes a method for using Linebacker™ formulations to inhibit inflammatory responses in conditions such as arthritis, asthma, and inflammatory bowel disease.
This is the first Linebacker™ patent issued in Canada, with an expiration date in May 2037. CEO Frank D. Heuszel highlighted the significance of this achievement, noting that the Canadian Inflammatory Disease Treatment Market was estimated at $7B in 2022.
Positive
- Issuance of Canadian Patent #3,024,728 for Linebacker™ technology
- Patent covers novel compounds and compositions for treating inflammatory diseases
- Potential for reduced side effects compared to traditional anti-inflammatory medications
- First Linebacker™ patent issued in Canada, expiring in May 2037
- Strengthens company's IP portfolio in a market estimated at $7B in 2022
Negative
- None.
Details
News Market Reaction – IBO
The recorded move for IBO in the trading session of this news was +19.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker™ technology platform. The Canadian Intellectual Property Office has issued Canadian Patent #3,024,728 entitled “Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders". This patent includes claims to novel enhanced phenolic compounds and pharmaceutical compositions as well as their uses in treating inflammatory related diseases.
The Linebacker™ technology is a platform of small molecule compounds, which target key pathways in the inflammatory process, potentially reducing inflammation and providing symptomatic relief while reducing side effects often associated with traditional anti-inflammatory medications.
This patent also employs a method of using a Linebacker™ formulation of novel compounds, with potential to inhibit the inflammatory response and mitigate conditions such as arthritis, asthma, and inflammatory bowel disease. This marks the first Linebacker™ patent issued in Canada, emphasizing Impact BioMedical’s commitment to discovering, developing, and patenting unique technologies to address unmet needs in human healthcare. The term of this Canadian patent will expire in May 2037.
Frank D. Heuszel, CEO of Impact BioMedical, commented, "The Canadian Inflammatory Disease Treatment Market was estimated to be
About Impact BioMedical Inc.:
Impact BioMedical Inc. (“IBO”) discovers, confirms, and patents unique science and technologies resulting in new offerings in human healthcare and wellness. Once available, IBO works closely with licensing, co-development, joint ventures, and other relationships to bring these offerings to market. For more information, visit Impact BioMedical Inc. | Reverse Engineering Nature (impactbiomedinc.com).
About Linebacker™ : Linebacker™ is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Polyphenols are substances found in many nuts, vegetables, and berries. Linebacker™ compounds are modified myricetin, which is a common plant-derived flavonoid. Linebacker™ down-regulates PIM (proviral integration site for Moloney murine leukemia virus) kinase which plays a key role as an oncogene in solid tumor cancers. Composition and method patents are issued for Linebacker™ in the U.S. and other countries. Linebacker™ -1 and Linebacker™ -2 compounds have been licensed to ProPhase Laboratories for development and commercialization worldwide. Linebacker™ is a trademark of Impact BioMedical Inc.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations:
info@impactbiomedinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.